

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method for reducing bone resorption in an individual diagnosed to have ~~a disorder of bone resorption characterized by increased bone turnover~~osteoporosis, said method comprising administering an antagonist of placental growth factor to the individual in an amount effective to reduce ~~said bone turnover~~bone resorption.

2-9. (Cancelled)

10. (Currently Amended) The method according to claim 1, wherein said antagonist is selected from the group consisting of antibodies binding on placental growth factor, peptides binding on placental growth factor, tetrameric peptides binding on placental growth factor or VEGFR-1, small molecules binding on placental growth factor or VEGFR-1, anti-sense nucleic acids against placental growth factor or VEGFR-1, interference RNA against placental growth factor or VEGFR-1 and ribozymes against placental growth factor ~~or~~ and VEGFR-1.

11-13. (Cancelled)

14. (Withdrawn) A method to identify an individual with excessive bone resorption or a predisposition to acquire a disorder of excessive bone resorption, which comprises identifying a polymorphism of the PlGF promoter and/or elevated levels of PlGF in a sample of said individual.

15. (Previously Presented) The method according to claim 1, wherein said subject is a human.

16. (Currently Amended) A method for suppressing bone resorption in a ~~bone resorption disorder~~ osteoporosis, said method comprising contacting an osteoclast cell with an antagonist of placental growth factor ~~that inhibits bone turnover activity of the osteoclast cell~~ so that bone resorption ~~in the bone resorption disorder~~ is suppressed.

17. (Currently Amended) The method according to claim 16, wherein said antagonist is selected from the group consisting of antibodies binding on placental growth factor, peptides binding on placental growth factor, tetrameric peptides binding on placental growth factor or VEGFR-1, small molecules binding on placental growth factor or VEGFR-1, anti-sense nucleic acids against placental growth factor or VEGFR-1, interference RNA against placental growth factor or VEGFR-1 and ribozymes against placental growth factor ~~or~~ and VEGFR-1.

18. (Cancelled)